US biotechnology company developing biologic medicines, with an AI and data sciences capability center in Hyderabad, India.
amgen.comLegal name
Amgen Inc.
Founded
1980
Headquarters
Thousand Oaks, California, USA
Industry
Biotechnology and biopharmaceuticals
Employees
31,500 (2025)Revenue (FY25)
$36.75 billion
Market Cap
$196.66 billion
Listed on
NASDAQ: AMGN
CEO
Robert A. Bradway
Website
amgen.comAmgen Inc. is a US biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. It develops, manufactures, and markets biologic medicines for serious illnesses across areas such as oncology, cardiovascular disease, bone health, and inflammation. The company trades on the Nasdaq under the ticker AMGN and is a component of the Dow Jones Industrial Average.
For fiscal year 2025, Amgen reported revenue of about $36.75 billion, up roughly 10% from the prior year, with a market capitalization near $196.66 billion. The company employed about 31,500 people as of 2025. It is led by Robert A. Bradway, who serves as both Chairman and Chief Executive Officer, with Peter Griffith as Executive Vice President and Chief Financial Officer.
In India, Amgen operates a technology and innovation capability center in Hyderabad, located in HITEC City at the RMZ Spire Tower, focused on artificial intelligence and data sciences work for the global business. The India operations run under a local legal entity, Amgen Global Technology India Private Limited, incorporated in December 2024 and registered with the Registrar of Companies, Hyderabad.
Chairman and Chief Executive Officer
Executive Vice President and Chief Financial Officer
Executive Vice President, Operations
Executive Vice President, General Counsel and Secretary
Interview experience
Favorable
Interview difficulty
Medium
Interview process length
About a week
Practice real questions and get instant feedback before the real thing.
Q: Write a SQL query to identify patient drop-off points in a multi-stage enrollment funnel.
A: Model each stage as its own step, then use conditional counts or a series of LEFT JOINs from the first stage forward so patients who never reach a later stage still appear. Compare counts stage over stage to show where the largest drop happens.
Q: How do you optimize a slow-running SQL query when working with millions of rows of patient-level data?
A: Start by reading the execution plan to find full scans and expensive joins, then add or adjust indexes on the join and filter columns. Reduce the working set early with selective WHERE clauses, avoid SELECT star, and consider pre-aggregated or partitioned tables for repeated heavy reads.
Q: Can you explain the difference between a left join and an inner join using a practical healthcare claims example?
A: An inner join returns only claims that match a record in both tables, so a claim with no matching member row disappears. A left join keeps every claim from the left table and fills member fields with null when there is no match, which is what you want when you must not lose any claim.
Q: What key performance indicators would you track to assess payer coverage and reimbursement barriers for a newly launched drug?
A: Track prior authorization approval and denial rates, days to approval, patient out-of-pocket cost, formulary tier placement, and the share of covered lives by payer. Pair these with fill and abandonment rates at the pharmacy to see where access actually breaks down.
Practice real questions and get instant feedback before the real thing.
Total comp, L3 to L4
₹15.1L to ₹21L+ per year
Reported average
$116,817 per year
9 salaries Salaries submitted
Reported average
$139,033 per year
5 salaries Salaries submitted
Reported average
$88,441 per year
12 salaries Salaries submitted
Reported average
$107,083 per year
8 salaries Salaries submitted
Reported average
$153,107 per year
9 salaries Salaries submitted
See how your pay compares and find roles that match your target.
Hyderabad, India • Full-time
Hyderabad, India • Full-time
Hyderabad, India • Full-time
Hyderabad, India • Full-time
Hyderabad, India • Full-time
Hyderabad, India • Full-time
Tailor your resume to each Amgen role in minutes.
June 12, 2026
FDA moves to withdraw Amgen's Tavneos; Amgen defends the drug
The FDA is seeking to withdraw approval of Amgen's rare-disease drug Tavneos over liver-safety concerns and allegations the original developer manipulated trial data. Amgen requested a hearing and commissioned an independent analysis from the Duke Clinical Research Institute.
#FDA #Tavneos #RareDisease
View postApril 30, 2026
Amgen reports first quarter 2026 financial results
Amgen posted Q1 2026 total revenues of $8.6 billion, up 6% year over year, with non-GAAP diluted EPS of $5.15. The company set full-year 2026 revenue guidance of $37.1 billion to $38.5 billion.
#Earnings #Q12026 #AMGN
View postNovember 19, 2025
FDA grants full approval to Amgen's Imdelltra in small cell lung cancer
The FDA granted full approval to IMDELLTRA (tarlatamab-dlle) for extensive-stage small cell lung cancer in adults after platinum-based chemotherapy. The Phase 3 DeLLphi-304 study showed a 40% reduction in the risk of death versus chemotherapy.
#FDA #Oncology #Imdelltra
View postJune 23, 2025
Amgen presents Phase 2 MariTide obesity results at ADA sessions
Amgen reported that its monthly obesity candidate MariTide produced up to about 20% average weight loss over 52 weeks in people with obesity, with weight loss not yet plateaued at one year. Results were presented at the American Diabetes Association's 85th Scientific Sessions.
#Obesity #MariTide #ClinicalData
View postFebruary 24, 2025
Amgen opens technology and innovation site in Hyderabad
Amgen opened its technology and innovation center in HITEC City, Hyderabad, spanning about 524,000 square feet and focused on AI and data science to advance its medicine pipeline. The company committed $200 million in investment through 2025 with further investment planned.
#IndiaExpansion #Hyderabad #AI
View postAmgen is a biotechnology company that develops, manufactures, and markets biologic medicines for serious illnesses across oncology, cardiovascular disease, bone health, and inflammation.
